Advertisement
Screener

Traws Pharma, Inc. (TRAW) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.8 / 5 stars · 32/91 Roast Me

Traws Pharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Traws Pharma, Inc. (TRAW) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-14

  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 24 month
2026-06-300.00%
10-Q · filed 2026-08-14
2026-03-310.00%
10-Q · filed 2026-05-15
2025-12-310.00%
10-K · filed 2026-04-15
2025-09-300.00%
10-Q · filed 2025-11-13
2025-06-300.00%
10-Q · filed 2025-08-14
2025-03-310.00%
10-Q · filed 2025-05-15
2024-12-310.00%
10-K · filed 2026-04-15
2024-09-300.00%
10-Q · filed 2024-11-14
2024-06-300.00%
10-Q · filed 2024-08-15
2024-03-310.00%
10-Q · filed 2024-05-15
2023-12-310.00%
10-K · filed 2025-03-31
2023-09-300.00%
10-Q · filed 2024-11-14
2023-06-300.00%
10-Q · filed 2024-08-15
2023-03-310.00%
10-Q · filed 2024-05-15
2022-12-310.00%
10-K · filed 2024-04-01
2022-09-300.00%
10-Q · filed 2023-11-14
2022-06-300.00%
10-Q · filed 2023-08-14
2022-03-310.00%
10-Q · filed 2023-05-15
2021-12-310.00%
10-K · filed 2023-03-30
0.00%
10-K · filed 2022-03-21
2021-09-300.00%
10-Q · filed 2021-11-15
2021-06-300.00%
10-Q · filed 2021-08-16
2021-03-310.00%
10-Q · filed 2021-05-17
2020-12-310.00%
10-K · filed 2021-03-18
2020-09-300.00%
10-Q · filed 2020-11-16
2020-06-300.00%
10-Q · filed 2020-08-12
2019-12-310.00%
10-K · filed 2021-03-18
2018-12-310.00%
10-K · filed 2020-03-27
2017-12-310.00%
10-K · filed 2019-04-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alzamend Neuro, Inc. (ALZN)United States$0.009B
Imunon, Inc. (IMNN)United States$0.008B-0.56
SOLIGENIX, INC. (SNGX)United States$0.008B
FibroBiologics, Inc. (FBLG)United States$0.009B-0.27
EXICURE, INC. (XCUR)United States$0.008B-1.54
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B